Engineered Extracellular Vesicles As a New Delivery Platform for Migraine.

Migraine is a complicated neurovascular disorder that is hard to treat. The blood-brain barrier (BBB) complicates treatment options. Current therapies, like CGRP inhibitors, can help but have limitations. They may also cause unwanted side effects. This highlights the need for better treatment delivery methods. Researchers are exploring extracellular vesicles (EVs) as a new solution. EVs can cross the BBB more effectively than traditional methods. They can deliver targeted treatments directly to areas affected by migraines. This technology allows for multiple therapies to be delivered at once. The paper discusses how native EVs contribute to migraine development. Understanding this can help identify specific targets for new treatments. Overall, engineered EVs may revolutionize how migraine therapies are delivered and improve patient outcomes significantly. Clinical relevance: This research suggests that engineered extracellular vesicles could enhance migraine treatment effectiveness by delivering therapies directly to affected brain areas.